PRTN3 and kidney failure: In contrast, only 28% (2/7) of PR3-ANCA seropositive individuals with severely reduced kidney function or kidney failure (KDIGO stages 4–5) at diagnosis achieved KDIGO stage 3 by 12 months postdiagnosis and no PR3-ANCA seropositive individual improved to KDIGO stages 1–2.